



**TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION  
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)**

Madrid, 10 May 2023

In compliance with the information duties provided for in article 227 of the Law 6/2023, of 17 March, on Securities Market and Investment Services, Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, "**ROVI**" or the "**Company**") hereby discloses to the Spanish National Market Commission the following

**OTHER RELEVANT INFORMATION**

The Board of Directors of the Company has adopted, among others, the following resolutions:

- I.** To call shareholders to the Ordinary General Shareholder's Meeting, which is expected to be held on 14 June 2023, at 11:00 am, on first call, at calle Príncipe de Vergara 187, Plaza de Rodrigo Uría, 28002, Madrid.

Attendance at this corporate event may also be made remotely or virtually under the terms set out in the general meeting calling announcement.

- II.** The Company has published today the announcement of the call of the aforementioned Ordinary General Shareholder's Meeting on the Company's website ([www.rovi.es](http://www.rovi.es)), on the website of this Commission and in one of the most widely circulated newspapers in Spain, and has made available to the shareholders on the Company's website ([www.rovi.es](http://www.rovi.es)) said call, as well as the rest of the documentation related to the General Shareholder's Meeting.

- III.** To propose to the General Shareholder's Meeting, among other resolutions, the distribution of a dividend of EUR 1,2938 gross per share

entitled to receive it, charged to the 2022 results and the non-restricted reserves allocated in the account "Results from previous financial years".

The following documents are attached hereto:

- (i) the announcement of the call of the General Shareholder's Meeting; and
- (ii) the proposed resolutions of the board of Directors to be adopted, as the case may be, by the General Shareholder's Meeting.

It is hereby noted that shareholders can consult the documents relating to the aforementioned General Shareholder's Meeting of ROVI on the Company's website ([www.rovi.es](http://www.rovi.es)), where the rest of the documentation to be submitted to the General Shareholder's Meeting (including the relevant director's reports) will also be included.

In addition, kindly note that the annual financial statements and the individual and consolidated management reports of the Company and its group corresponding to the financial year 2022 that are submitted to the approval of the General Shareholder's Meeting, with the related audit reports, the statement of non-financial information included in the consolidated management report, the Annual Corporate Governance Report and the Annual Report on Remuneration of the Company's Directors corresponding to the financial year 2022, have already been sent to the Spanish National Securities Market Commission and have also been made available to the shareholders on the Company's website ([www.rovi.es](http://www.rovi.es)) together with the rest of the documentation that must be made available to the shareholders on the occasion of the call.

Mr. Juan López-Belmonte Encina  
Chairman of the Board of Directors and Chief Executive Officer  
Laboratorios Farmacéuticos ROVI, S.A.



**LABORATORIOS FARMACÉUTICOS ROVI, S.A.**  
**GENERAL SHAREHOLDERS' MEETING**

The Board of Directors of LABORATORIOS FARMACÉUTICOS ROVI, S.A. ("**ROVI**" or the "**Company**") hereby calls its shareholders to the Ordinary General Meeting to be held at calle Príncipe de Vergara 187, Plaza de Rodrigo Uría, 28002, Madrid, at 11 a.m. on 14 June 2023, on first call and, if applicable, on the following day, 15 June 2023, at the same place and time on second call. This corporate event may also be attended remotely or electronically under the terms indicated in this announcement.

The following are the matters to be deliberated and voted on at this General Shareholders' Meeting:

**AGENDA**

1. Examination and, if appropriate, approval of the individual financial statements of the Company (balance sheet, income statement, statement of changes in equity, statement of cash flows and notes to the financial statements) and of the consolidated financial statements of the Company with its subsidiaries (consolidated balance sheet, consolidated income statement, consolidated statement of comprehensive income, consolidated statement of changes in equity, consolidated statement of cash flows and consolidated notes to the financial statements) and of the consolidated management report of the Company with its subsidiaries, all for the year ended 31 December 2022.
2. Examination and, if appropriate, approval of the statement of non-financial information included in the consolidated management report of the Company with its subsidiaries for the year ended 31 December 2022.
3. Examination and, if appropriate, approval of the proposal for the application of the individual profit for the year ended 31 December 2022 and the proposal for the final dividend.
4. Examination and, if appropriate, approval of the management work and performance of the Board of Directors during the year ended 31 December 2022.
5. Composition of the Board of Directors: Ratification and/or re-election, if appropriate, of directors for the term determined in the bylaws.
  - 5.1. Re-election, if appropriate, of Mr Marcos Peña Pinto as an external independent director for the term determined in the bylaws.
  - 5.2. Ratification and re-election, as appropriate, of Ms Teresa Corzo Santamaría as external independent director for the term determined in the bylaws.
6. Examination and approval, if appropriate, of the maximum annual remuneration of the members of the Board of Directors in their capacity as such for 2023.
7. Examination and approval, if appropriate, of the re-election of the auditors of the Company and its consolidated group for 2023.
8. Delegation of powers to formalise and register the resolutions adopted by the General Shareholders' Meeting and to carry out the mandatory filing of the financial statements.



ADVISORY ITEM

9. Annual report on the remuneration of directors of the Company:

**MEASURES FOR IN-PERSON ATTENDANCE AT THE GENERAL SHAREHOLDERS' MEETING**

Please note that there may be limitations on the maximum capacity and number of attendees at this type of event. This could result in an inability to enter the Meeting's premises once the capacity applicable at the time of the meeting has been reached. In the event that access to the meeting is not possible because the capacity limit has been reached, shareholders or their proxies are advised that at that time it may no longer be possible to participate through the alternative channels if they have already been closed for registration in accordance with the deadlines and procedures described in this notice. For this reason it is especially advisable to participate through any of the alternative channels under the terms provided in this notice.

For further information, shareholders may contact the Company by sending an e-mail to [departamentolegal@rovi.es](mailto:departamentolegal@rovi.es).

**SUPPLEMENT TO THE CALL AND SUBMISSION OF PROPOSALS**

Shareholders representing at least three percent of the share capital may request the publication of a supplement to this notice, including one or more items on the Agenda, provided that the new items are accompanied by an explanation or, as the case may be, an explained proposed resolution. The exercise of this right must be made by means of reliable notification to be received at the registered office of ROVI (Laboratorios Farmacéuticos Rovi, S.A., Junta General, c/ Julián Camarillo, 35, 28037, Madrid) within the five days following the publication of this notice.

Likewise, shareholders representing at least three percent of the share capital may, within the same period of five days following the publication of this notice, submit reasoned proposals for resolutions on matters included or which should be included on the Agenda pursuant to the provisions of Article 519.3 of the Corporate Enterprises Act.

The notification letter shall state the name or corporate name of the requesting shareholder or shareholders, and shall be accompanied by the appropriate documentation -a copy of the attendance, proxy and remote voting card (the "**attendance card**") or certificate of ownership - proving their status as shareholder, in order to check this information with that provided by Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A.U. ("**IBERCLEAR**"), as well as the content of the matter(s) raised by the shareholder or the content of the proposal(s) made by the shareholder.

In the event that the shareholder raises any new items on the Agenda, the shareholder may be required to also attach the proposal(s) and the supporting report(s) of proposals to which the items included in the supplement refer in cases in which it is legally required.

The supplement to the notice of meeting shall be published at least fifteen days prior to the date set for the meeting to be held.

**IN-PERSON ATTENDANCE AT THE GENERAL MEETING**

Shareholders may attend the General Shareholders' Meeting regardless of the number of shares they own, provided that the shares are registered in their name in the corresponding book-entry register five days prior to the date on which the Meeting is to be held (i.e. 9 June, if the General Meeting is to be held on first call, as scheduled), and must provide proof of such fact at the entrance to the premises where the General Meeting is to be held from two hours prior to the scheduled start time of the meeting. In

*THIS TRANSLATION IS FOR INFORMATION PURPOSES ONLY.  
IN THE EVENT OF ANY DISCREPANCY BETWEEN THE SPANISH VERSION AND THE ENGLISH  
VERSION, THE SPANISH VERSION SHALL PREVAIL.*



order to exercise the right to attend, the shareholder must obtain the corresponding attendance card indicating the number, class and series of the shares he/she owns, as well as the number of votes he/she may cast. The attendance card will be issued by the entities participating in IBERCLEAR in favour of the holders of the shares who can prove that they have them registered five days prior to the date on which the Meeting is to be held.

For the purpose of proving the identity of the shareholders, or whoever validly represents them, at the entrance to the premises where the General Shareholders' Meeting is held, the attendees may be asked, together with the presentation of the attendance card, to prove their identity by presenting their National Identity Document or any other official document in force and generally accepted for such purposes.

### **REMOTE ATTENDANCE OR ATTENDANCE BY ELECTRONIC MEANS AT THE GENERAL SHAREHOLDERS' MEETING**

The mechanisms for attending the Meeting by electronic means will be opened in the space dedicated to the General Shareholders' Meeting 2023 ("*Electronic attendance*") on the Company's website ([www.rovi.es](http://www.rovi.es)) in the terms indicated below:

1. **Pre-registration:** in order to guarantee the identity of the attendees, the correct exercise of their rights and the proper functioning of the meeting, shareholders who wish to use the electronic attendance mechanisms must pre-register in the space dedicated to the 2023 General Shareholders' Meeting ("*Electronic attendance*") of the corporate website, from 10 a.m. on 10 May 2023 until 11:59 p.m. on 13 June 2023, without prejudice to what is indicated below for proxies. After that time, no pre-registration will be accepted for the exercise of the right to electronic attendance.

Pre-registration will be carried out by means of a qualified electronic signature, under the terms of Law 6/2020, of 11 November, regulating certain aspects of electronic trust services, provided that it is based on a recognised electronic certificate in relation to which there is no record of its revocation and that (i) it is an Electronic User Certificate issued by the Spanish Public Certification Authority (CERES) under the Spanish Mint or (ii) it is incorporated to the National Electronic Identity Document issued in accordance with Royal Decree 1553/2005, of 23 December 2005, which regulates the issuance of the National Identity Document (DNI) and its electronic signature certificates.

If the person attending remotely, whether or not he/she is a shareholder, has been granted proxies, in order to exercise the rights inherent to such proxies, he/she must have notified the Company before 24 hours prior to the holding of the General Meeting, that is, before 13 June at 11 a.m., by electronic means (by e-mail to the address [departamentolegal@rovi.es](mailto:departamentolegal@rovi.es)) or by post (c/ Julián Camarillo, 35, 28037, Madrid), indicating that they accept said proxies and identifying themselves by sending the attendance, proxy and remote voting card duly completed, and a copy of the proxy's DNI, NIE or passport, so that their identity can be proved on the day the Meeting is held. For clarification purposes, the representatives attending remotely shall be pre-registered by sending such e-mail or postal mail to the Company, in the manner and by the deadline indicated herein, once the Company has confirmed their pre-registration.

The Company reserves the right to request from the shareholders any additional means of identification that it deems necessary to duly guarantee the identity of the shareholders, verify their status as shareholders and guarantee the authenticity of the vote or proxy.



Once the shareholder or, as the case may be, their representative, has pre-registered in accordance with the indicated means and within the established period, they may attend and vote at the General Meeting through electronic means by making the corresponding registration-connection on the day the General Meeting is held.

2. Registration-connection and attendance: in order to allow for the proper management of the electronic attendance systems, the shareholder or proxy who has pre-registered to attend the General Meeting electronically in accordance with section (1) above, must register in the space dedicated to the 2023 General Shareholders' Meeting ("*Electronic attendance*") on the Company's corporate website between 9 a.m. and 11 a.m. on 14 June 2023 (if, as expected, the General Meeting is held on first call) or on 15 June 2023 (if the General Meeting is held on second call) and identify himself/herself by means of a recognised electronic signature in accordance with one of the means provided in section (1), second paragraph above or as indicated in the corresponding instructions. Attendee registration will not be accepted outside this time slot.

In the event that on 14 June 2023, it is determined that there is not sufficient quorum to hold the General Shareholders' Meeting on first call, the Company will publish this circumstance through the space dedicated to the 2023 General Shareholders' Meeting on the Company's corporate website confirming that the General Shareholders' Meeting will be held on second call. In the event that the General Meeting is held on second call, those attending by electronic means who have registered on first call must register again in order to attend the General Meeting electronically on second call.

A shareholder or assistant representative who has registered to attend remotely and wishes to express to the Notary or supporting personnel (or, in his/her absence, to the Secretary of the General Shareholders' Meeting) his/her express abandonment of the Meeting, they must do so by means of the form provided for such purpose in the remote attendance computer application. Once he/she has informed the Notary of his/her express will to leave the meeting, all subsequent actions shall be deemed not to have been carried out.

3. Speaking rights: in accordance with the provisions of the Corporate Enterprises Act, the interventions and proposed resolutions or requests for information or clarifications that, in accordance with the Law, shareholders or proxies attending by electronic means intend to make, must be sent to the Company, in writing and in any case, in the form, terms and conditions established on the aforementioned website of the Company, from 9 a.m. on 14 June 2023 or, as the case may be, on 15 June 2023, depending on whether the General Meeting is held on first or second call, respectively, and until the time at which the Chairman or, as the case may be, the Secretary of the Meeting announces the beginning of the round of speaking turns for shareholders attending the General Meeting in person.

Those attending by electronic means who wish their contribution to be recorded verbatim in the minutes of the Meeting must expressly indicate this in the text of the contribution.

Requests for information or clarification from shareholders attending by electronic means may be answered verbally during the General Meeting and, in any case, in writing during the seven days following the Meeting, in accordance with the provisions of the Corporate Enterprises Act.

In the event that the General Meeting is held on second call, attendees by electronic means who, having connected to the meeting on first call, have sent contributions and proposed resolutions or requests for information or clarifications, must send them again the following day, under the terms indicated in this section (3); otherwise, they shall be deemed not to have been made.

THIS TRANSLATION IS FOR INFORMATION PURPOSES ONLY.  
IN THE EVENT OF ANY DISCREPANCY BETWEEN THE SPANISH VERSION AND THE ENGLISH  
VERSION, THE SPANISH VERSION SHALL PREVAIL.



4. Voting: Voting on the proposals relating to items included in the Agenda may be cast from the time the shareholder or, as the case may be, the proxy registers as an attendee on the day of the Meeting until the Chairman or, as the case may be, the Secretary of the Meeting announces that voting on the proposed resolutions relating to the items included in the Agenda has commenced.

Regarding the proposed resolutions on those matters which, by legal mandate, need not appear on the Agenda, those attending by electronic means may cast their votes as from the moment at which said proposals are read out for voting and until the Chairman or, as the case may be, the Secretary of the Meeting, announces that the voting period for said proposed resolutions has commenced.

Voting on the proposed resolutions shall be carried out through the web page and in accordance with the corresponding voting form. The shareholder must indicate the direction of his vote for each of the items included in the Agenda. If, in relation to any of the items on the Agenda, the shareholder does not indicate the vote decision, it shall be understood that they are voting in favour of the proposals made by the Board of Directors.

In any case, the remote voting process for all proposals submitted to the Meeting shall end when the reading of the summaries of the proposed resolutions by the Secretary of the Meeting and the voting on the proposals begins.

In matters not expressly regulated in this notice, the same rules on voting and the adoption of resolutions set forth in the Regulations of the General Shareholders' Meeting for face-to-face meetings shall apply to shareholders attending the Meeting by electronic means, adapted, where appropriate, to the special features that may arise from the electronic nature of this Meeting.

5. Other matters: the Company may adapt, with the due guarantees, the means to allow electronic attendance at the General Shareholders' Meeting in the case of shareholders not residing in Spain, qualified investors and other similar cases.

Electronic attendance at the General Shareholders' Meeting renders proxy or voting by remote means of communication prior to the General Shareholders' Meeting null and void.

In the event of concurrence of co-owners of a securities depository, the one who registers first shall be considered the attendee and, therefore, any subsequent access by the remaining co-owners shall be denied. For the purposes of Article 126 of the Corporate Enterprises Act, it is presumed that the co-owner who is registered first is designated by the rest of the co-owners to exercise the shareholder rights.

It is the sole responsibility of the shareholder (or his representative) to keep the means of identification necessary to access and use the electronic attendance service. In the case of a legal entity, the latter must notify any modification or revocation of the powers held by its representative and, therefore, the Company declines any liability until such notification is made.

The Company reserves the right to modify, suspend, cancel or restrict the mechanisms for electronic representation or voting and/or electronic attendance at the Meeting when technical or security reasons so require or impose, both for the granting of proxies and the casting of votes through remote means of communication and for remote attendance at the Meeting.

The Company shall not be liable for any damages that may be caused to the shareholder as a result of breakdowns, overloads, line failures, connection failures or any other eventuality of the same or a similar nature, beyond the Company's control, that prevent the use of the mechanisms



for electronic representation or voting and/or remote attendance at the Meeting. Therefore, such circumstances shall not constitute an illegitimate deprivation of the shareholder's rights, without prejudice to the adoption of such measures as each situation may require, including the possible temporary suspension or extension of the Meeting if necessary to ensure the full exercise of their rights by the shareholders or their representatives.

## **PROXY, DELEGATION AND VOTING RIGHTS THROUGH REMOTE MEANS OF COMMUNICATION**

### **I. Proxy and delegation through remote means**

In accordance with the provisions of Articles 30 of the Company's Bylaws and 12 of the Regulations of the General Meeting, any shareholder entitled to attend may be represented at the General Meeting by another person, even if not a shareholder of the Company, pursuant to the requirements and formalities required by law, the Bylaws and other applicable internal regulations of the Company.

The proxy must be completed and signed by the shareholder, subscribing the corresponding attendance, proxy and voting card issued by the entity participating in IBERCLEAR and, if applicable, the document extracted from the corporate website.

The person in whose favour the proxy is granted must exercise it either by attending the Meeting in person and presenting the attendance card issued by the entity participating in IBERCLEAR at the shareholders' registration desks, at the place and on the day set for the holding of the General Meeting, from two hours before the scheduled start time of the meeting; or by attending the Meeting electronically under the terms of the section on "Remote attendance or attendance by electronic means at the General Meeting".

Proxies are always revocable. Attendance at the Meeting by the represented shareholder, whether in person, electronically or by remote voting, entails the revocation of any proxy, regardless of the date of the proxy. In the event that a shareholder makes several proxies or casts several votes, the last proxy or the last vote cast that has been received by the Company within the established term shall prevail.

The proxy must be conferred specifically for each General Meeting, in writing and may be conferred by means of remote communication.

In the event that instructions have been issued by the represented shareholder, the proxy shall vote in accordance with such instructions and shall be obliged to keep such instructions for one year from the date of the Meeting.

The proxy may represent more than one shareholder without limitation as to the number of shareholders represented. When a proxy holds proxies for several shareholders, he/she may cast differing votes according to the instructions given by each shareholder.

In any case, the number of shares represented shall be computed for the valid convening of the Meeting.

The documents containing the proxies for the General Meeting shall include, at least, the following mentions:

- (a) Date of the General Meeting and the Agenda.
- (b) Identity of principal and proxy. If not specified, it shall be understood that the proxy has been granted, indistinctly, in favour of the Chairman of the Board of Directors (or, in their absence, the Chairman of the General Shareholders' Meeting), or the Secretary of the Board of Directors, without prejudice to what is indicated below in the event of a conflict of interest.
- (c) Number of shares owned by the shareholder granting the proxy.

THIS TRANSLATION IS FOR INFORMATION PURPOSES ONLY.  
IN THE EVENT OF ANY DISCREPANCY BETWEEN THE SPANISH VERSION AND THE ENGLISH  
VERSION, THE SPANISH VERSION SHALL PREVAIL.





- (d) The instructions on how the shareholder granting the proxy is to vote on each of the items on the Agenda, as the case may be.

The Chairman of the General Shareholders' Meeting or the persons appointed through him shall be empowered to determine the validity of the proxies granted and compliance with the requirements for attendance at the General Shareholders' Meeting.

The provisions of the preceding paragraphs shall not be applicable when the proxy is the spouse, ascendant or descendant of the represented party and so proves; nor when the representative holds general powers of attorney conferred in a public deed with powers to administer all the assets that the principal holds in Spain and so provides.

When conferred by means of remote communication, only the representation made as follows shall be considered valid:

### **1. By postal correspondence**

The attendance, proxy and voting card issued by the entity participating in IBERCLEAR, duly signed and completed by the shareholder, shall be sent to the Company's domicile (Laboratorios Farmacéuticos Rovi, S.A., General Meeting, c/ Julián Camarillo, 35, 28037, Madrid). The proxy granted and the identity of the principal shall be stated.

In the event that the attendance card issued by the entity participating in IBERCLEAR does not include the section relating to the proxy or it is incomplete, the shareholder may use the attendance card made available to the shareholders by the Company on its website ([www.rovi.es](http://www.rovi.es)). Said attendance card, duly signed, must be sent to the Company by post to the address indicated in the previous paragraph, together with the corresponding attendance card issued by the entity participating in IBERCLEAR, duly signed.

### **2. By electronic communication**

Proxies granted by electronic communication shall be admitted as of 10 May 2023 through the Company's website ([www.rovi.es](http://www.rovi.es)), by accessing the dedicated space and following the procedure established therein.

To do so shall require a qualified electronic signature, under the terms of Law 6/2020, of 11 November, regulating certain aspects of electronic trust services, provided that it is based on a recognised electronic certificate in relation to which there is no record of its revocation and that (i) it is an Electronic User Certificate issued by the Spanish Public Certification Authority (CERES) under the Spanish Mint or (ii) it is incorporated to the National Electronic Identity Document issued in accordance with Royal Decree 1553/2005, of 23 December 2005, which regulates the issuance of the National Identity Document and its electronic signature certificates.

## **II. Voting rights and the exercise of remote voting rights**

Shareholders with the right to attend and vote may cast their vote on the proposals relating to items included in the Agenda prior to the Meeting, by post or electronic communication, in accordance with the terms set forth in the Law, in Articles 32 and 34 of the Bylaws and in Articles 10 and 24 of the Regulations of the General Shareholders' Meeting.

### **1. Voting by postal correspondence**

In order to vote by post, the shareholder must complete and sign the attendance card issued to him/her by the entity participating in IBERCLEAR, in which he/she will state his/her vote -in favour, against, abstention or blank-, marking with a cross in the corresponding box of the table that will appear in the attendance card issued by the entity participating in IBERCLEAR.

THIS TRANSLATION IS FOR INFORMATION PURPOSES ONLY.  
IN THE EVENT OF ANY DISCREPANCY BETWEEN THE SPANISH VERSION AND THE ENGLISH  
VERSION, THE SPANISH VERSION SHALL PREVAIL.



Once completed and signed, the shareholder must send it by post to the Company's address (Laboratorios Farmacéuticos Rovi, S.A., Junta General, c/ Julián Camarillo, 35, 28037, Madrid).

In the event that the attendance card issued by the entity participating in IBERCLEAR does not include the section relating to remote voting or it is incomplete, the shareholder may use the attendance card made available to the shareholders by the Company on its website ([www.rovi.es](http://www.rovi.es)). Said attendance card, duly signed, must be sent to the Company by post to the address indicated in the previous paragraph, together with the corresponding attendance card issued by the entity participating in IBERCLEAR, duly signed.

## **2. Voting by electronic communication**

A shareholder may also cast their vote by means of electronic communication authorized with his legally recognized electronic signature under the same terms provided for in section I.2 above to grant proxy and in section III below. The vote shall be cast by means of a communication to the Company through its website ([www.rovi.es](http://www.rovi.es)) by accessing the space provided for this purpose and following the procedure established therein. The Company will send the shareholder casting their vote an electronic confirmation of the receipt of the vote.

## **III. Proxies, delegation and voting through remote means: common provisions**

In order to be valid, a proxy granted and a vote cast by any means of remote communication (postal or electronic) must be received by the Company by 11:59 p.m. on the day immediately prior to the day scheduled for the General Shareholders' Meeting. Otherwise, the proxy shall be deemed not to have been granted and the vote shall be deemed not to have been cast. After the aforementioned deadline, only votes cast in person or by electronic means at the General Shareholders' Meeting by the shareholder or by the person validly representing him/her shall be admissible.

In the event of in-person attendance, on the day and at the place where the Meeting is to be held, the appointed proxies, whether by postal correspondence or electronic communication, must identify themselves. They may do so from two hours prior to the scheduled time of the Meeting, by means of their National Identity Card or any other valid official document generally accepted for these purposes, in order that the Company may verify the representation conferred, along with a copy of the attendance card issued by the entity participating in IBERCLEAR sent to the Company (by post) or of the electronic document that the shareholder has filled in on the Company's website to confer the proxy.

In the event of attendance by electronic means, the proxy-holder who has pre-registered in accordance with paragraph (1) of the section of this Notice "**Remote Attendance or Attendance by Electronic Means at the General Meeting**" must register in the space dedicated to the 2023 General Shareholders' Meeting ("Electronic Attendance") on the Company's corporate website between 9 a.m. and 11 a.m. on the day the Meeting is held and identify him/herself by means of a recognised electronic signature in accordance with the provisions of paragraph (2) of said section. At the time of pre-registration, the designated proxies, whether by post or electronic communication, must identify themselves by sending the duly completed attendance, proxy and remote voting card and a copy of the representative's ID card, NIE or passport, so that their identity can be verified on the day of the Meeting. Otherwise, the proxies shall be deemed not to have been made. For explanatory purposes, any proxies attending by electronic means must notify the Company of the proxies granted before the period of 24 hours preceding the holding of the General Meeting, that is, before 13 June at 11 a.m., by electronic means (by e-mail to the address [departamentolegal@rovi.es](mailto:departamentolegal@rovi.es)) or by post (c/ Julián Camarillo, 35, 28037, Madrid), indicating that they accept said proxies and identifying themselves by sending the attendance, proxy and remote voting card



duly completed, and a copy of the proxy's DNI, NIE or passport, so that their identity can be proved on the day the Meeting is held.

When the shareholder exercises their voting rights or grants his proxy using remote means of communication, their shares must be recorded in their name in the corresponding book-entry register at least five days prior to the date on which the General Meeting is scheduled to be held.

Likewise, the validity of the proxy granted and of the vote cast by remote communication is subject to the verification -with the file provided by IBERCLEAR- of the shareholder's status as a shareholder. In the event of discrepancy between the number of shares communicated by the shareholder granting the proxy or casting his vote by remote communication and the number recorded in the book-entry records communicated by IBERCLEAR, the number of shares provided by the latter entity shall be deemed valid for quorum and voting purposes, unless there is evidence to the contrary.

The proxy granted and the vote cast by postal or electronic correspondence may be expressly revoked by the shareholder using the same means used to grant the proxy or cast the vote, within the established term.

Prior to appointment, the proxy must inform the shareholder in detail if there is a conflict of interest situation. If the conflict is subsequent to the appointment and the represented shareholder has not been advised of its possible existence, they must be informed immediately. In either case, if no new precise voting instructions have been received for each of the matters on which the proxy must vote on behalf of the shareholder, the proxy must abstain from voting.

For the purposes of the provisions of Articles 523 and 526 of the Corporate Enterprises Act, we note that the Chairman of the Meeting, as well as any other member of the Board of Directors, may have a conflict of interest (i) with respect to items 4 (Examination and, if appropriate, approval of the management work and performance of the Board of Directors during the year ended 31 December 2022), 5.1 (Re-election, if appropriate, of Mr Marcos Peña Pinto as an external independent director for the term determined in the bylaws), 5.2 (Ratification and re-election, as appropriate, of Ms Teresa Corzo Santamaría as external independent director, for the term determined in the bylaws), 6 (Examination and, if appropriate, approval of the maximum annual remuneration of the members of the Board of Directors in their capacity as such for 2023) and 9 (Submission to an advisory vote of the annual report on directors' remuneration) of the Agenda; and (ii) in the cases set forth in sections a), b), c) and d) of article 526.1 of the Corporate Enterprises Act (appointment, re-election or ratification of directors, removal, separation or dismissal of directors, exercise of corporate action for liability and approval or ratification of transactions of the company with director in question) that may be presented outside the Agenda in accordance with the Law. In relation to all of them, if the represented party has not given precise voting instructions, the proxy, unless expressly stated otherwise, shall be deemed to be conferred, jointly and severally and successively, on the Chairman of the General Shareholders' Meeting, the Chairman of the Audit Committee, the Chairman of the Appointments and Remuneration Committee and, if they are in turn in a situation of conflict of interest, the Secretary of the General Shareholders' Meeting.

In the event that a shareholder grants a proxy by means of postal correspondence or electronic communication to the Company, the directors or the Secretary of the Board, such proxy shall be deemed to be accepted upon receipt by the Company of such validly executed proxy within the term established in the first paragraph of this section and if the proxy does not include instructions for the vote or if any doubts arise as to the addressee or scope of the proxy, it shall be understood that (i) the proxy is made, without distinction, in favour of the Chairman of the Board of Directors (or, in the absence of the latter, the Chairman of the General Shareholders' Meeting) or the Secretary of the Board of Directors; (ii) it

*THIS TRANSLATION IS FOR INFORMATION PURPOSES ONLY.  
IN THE EVENT OF ANY DISCREPANCY BETWEEN THE SPANISH VERSION AND THE ENGLISH  
VERSION, THE SPANISH VERSION SHALL PREVAIL.*



refers to all the proposals made by the Board of Directors; (iii) it calls for a vote in favour thereof; and (iv) it also extends to the items that may arise outside the Agenda, in respect of which the proxy shall exercise the vote in the sense that he/she understands to be most favourable to the interests of the shareholder represented, within the framework of the corporate interest.

Likewise, any shareholder who casts their vote by post or electronic communication and does not make a mark in any or none of the boxes intended to indicate his vote with respect to the items on the Agenda shall be deemed to vote in favour of the respective proposals made by the Board of Directors.

The following rules of priority are established between proxy, remote voting and presence at the Meeting:

- (a) Attendance at the Meeting, either in person or electronically, of the shareholder himself who had previously granted a proxy or cast a vote remotely, regardless of the means used to cast it, shall render such proxy or vote null and void. In-person attendance will render electronic attendance null and void.
- (b) In the event that a shareholder makes several proxies or casts several votes, the last proxy or the last vote cast that has been received by the Company within the established term shall prevail.
- (c) As a particular rule, a vote cast by any means of remote communication shall render ineffective any granting of a proxy electronically or by means of a printed paper card, whether previously, which shall be deemed revoked, or subsequently, which shall be deemed not to have been cast.
- (d) Both the proxy and the vote cast remotely shall be rendered ineffective by the disposal of the shares conferring the right of attendance of which the Company is aware.

The Company will make available to the shareholders on its website ([www.rovi.es](http://www.rovi.es)) the forms to be used for proxy and voting by postal correspondence or remote electronic communication, under the terms set forth in this notice.

Any of the co-owners of a share deposit may vote, delegate or attend, and the priority rules set forth above shall apply among them. For the purposes of Article 126 of the Corporate Enterprises Act, it is presumed that the co-owner who at any time takes an action (attendance, proxy appointment or vote) is designated by the rest of the co-owners to exercise the rights of shareholder.

In the event the shareholder is a legal entity, the latter must notify the Company of any modification or revocation of the powers held by its representative and, therefore, the Company declines any liability until such notification is made.

The shareholder shall bear sole responsibility for custody of their electronic signature.

The Company reserves the right to modify, suspend, cancel or restrict the remote voting and proxy mechanisms when technical or security reasons so require or impose.

Laboratorios Farmacéuticos Rovi, S.A. shall not be liable for any damages that may be caused to the shareholder as a result of breakdowns, overloads, line failures, connection failures, failure of the postal service or any other eventuality of the same or a similar nature, beyond the Company's control, that prevent the use of the mechanisms for remote voting and delegation.

With respect to legal entity shareholders, when postal mail is the means of remote communication used to grant proxy to a third party or to vote, at the request of the Company, a copy of the powers of attorney of the natural person who in the name and on behalf of such legal entity shareholder grants the proxy to a third party or exercises the right to vote remotely must be sent together with the other documentation required in accordance with these rules.

*THIS TRANSLATION IS FOR INFORMATION PURPOSES ONLY.  
IN THE EVENT OF ANY DISCREPANCY BETWEEN THE SPANISH VERSION AND THE ENGLISH  
VERSION, THE SPANISH VERSION SHALL PREVAIL.*



## **RIGHT TO INFORMATION**

Pursuant to Article 518 of the Corporate Enterprises Act, from the publication of the notice of the Meeting until the Meeting is held, the following documents and information, inter alia, will be continuously available to the shareholders through the Company's website ([www.rovi.es](http://www.rovi.es)):

- Notice of call.
- Total number of shares and voting rights on the date of the call.
- Full text of the proposed resolutions to be adopted, as the case may be, by the Ordinary General Shareholders' Meeting of the Company in relation to each of the items included in the Agenda, together with the corresponding reports of the Board of Directors explaining the proposed resolutions under item Five of the Agenda:
  - Report of the Board of Directors of the Company on the justification of the reasoned proposal for the re-election as director of Mr Marcos Peña Pinto, together with the mandatory proposal report of the Appointments and Remuneration Committee, in which the competencies, experience and merits of the director whose re-election is proposed are assessed, including the identity, *curriculum vitae* and category of the director.
  - Report of the Board of Directors of the Company on the justification of the reasoned proposal for the ratification and re-election as director of Ms Teresa Corzo Santamaría, together with the mandatory proposal report of the Appointments and Remuneration Committee, in which the competencies, experience and merits of the director whose re-election is proposed are assessed, including the identity, *curriculum vitae* and category of the director.
- Annual Financial Report for 2022, which includes the individual and consolidated financial statements, the individual and consolidated management reports, and the respective auditors' reports for 2022.
- Statement of non-financial information included in the consolidated management report of the Company with its subsidiaries for the year ended 31 December 2022.
- Annual Corporate Governance Report for 2022.
- Annual Report on the Remuneration of the Company's Directors for 2022, which is submitted to an advisory vote as a separate item on the Agenda.
- Form or model of attendance, proxy and remote voting card.
- Valid requests for information, clarifications or questions made, as the case may be, by the shareholders in the exercise of their right to information and the answers provided by the directors, as the case may be.

Furthermore, in accordance with Article 272 of the Corporate Enterprises Act, any shareholder may obtain from the Company, as from the call of the General Shareholders' Meeting, immediately and free of charge, the documents to be submitted to the approval of the General Shareholders' Meeting in the legally applicable cases and, in particular, the Annual Financial Report for 2022, which includes the individual and consolidated financial statements, the individual and consolidated management reports, and the respective auditors' reports for 2022. Shareholders who wish to obtain copies of some or all of the above documents should send their request by e-mail to [departamentolegal@rovi.es](mailto:departamentolegal@rovi.es).



In accordance with Articles 197 and 520 of the Corporate Enterprises Act, from the date of publication of the notice of the General Shareholders' Meeting and up to and including the fifth day prior to the date scheduled for the Meeting the shareholders may request from the Board of Directors, regarding the matters included in the Agenda, the information or clarifications they deem necessary, or submit in writing the questions they deem pertinent, or verbally during the Meeting in the event of in-person attendance.

In addition, with the same advance notice and in writing or verbally during the Meeting in the event that they attend in person, the shareholders may request the clarifications they deem necessary regarding the information accessible to the public that the Company has provided to the National Securities Market Commission since the holding of the last General Shareholders' Meeting and regarding the auditor's report.

In the event that the information, clarifications or questions referred to in the above paragraphs are requested by electronic means, the manner and the periods indicated in this notices shall be observed.

Except in the cases expressly provided for in the Law, the Board of Directors shall be obliged to provide the requested information in writing until the day of the General Shareholders' Meeting and, in the case of requests made electronically, when appropriate, or verbally during the holding of the Meeting. When it is not possible to satisfy the shareholder's right at that time, the Board of Directors shall be obliged to provide such information in writing within seven days following the end of the Meeting.

Requests for information may be made by delivering the request at the Company's registered office; by sending it to the Company by post to Laboratorios Farmacéuticos Rovi, S.A., Junta General, at the address c/ Julián Camarillo, 35, 28037, Madrid; or by remote electronic communication through ROVI's website ([www.rovi.es](http://www.rovi.es)) in the place and manner established for that purpose.

Requests shall be accepted where the electronic document pursuant to which information is requested includes the shareholder's legally recognised electronic signature, under the terms of Law 6/2020, of 11 November, regulating certain aspects of electronic trust services, provided that it is based on a recognised electronic certificate in relation to which there is no record of its revocation and that (i) it is an Electronic User Certificate issued by the Spanish Public Certification Authority (CERES) under the Spanish Mint or (ii) it is incorporated to the National Electronic Identity Document issued in accordance with Royal Decree 1553/2005, of 23 December 2005, which regulates the issuance of the National Identity Document and its electronic signature certificates.

Whichever means is used to issue requests for information, the shareholder's request must include his name and surnames, together with proof of the shares he holds, by means of a copy of the attendance card issued by the entity participating in IBERCLEAR or certificate of ownership, so that this information may be checked against the list of shareholders and the number of shares in his name provided by IBERCLEAR, for the General Meeting in question. The shareholder shall be responsible for proving that the request has been sent to the Company in due time and form.

The Company's website will provide the pertinent explanations for the exercise of the shareholder's right to information under the terms set forth in the applicable regulations.

Requests for information shall be answered, once the identity and shareholder status of the applicant has been verified, prior to the General Shareholders' Meeting through the same means in which they were made, unless the shareholder indicates a different means that is considered suitable for this purpose. In any case, the directors may send the information in question by certified mail with acknowledgment of receipt or by registered fax.



## **ELECTRONIC SHAREHOLDER FORUM**

Pursuant to Article 539.2 of the Corporate Enterprises Act and in the terms referred to therein, in order to facilitate shareholder communication prior to the holding of the General Shareholders' Meeting, an Electronic Shareholders' Forum (the "Forum") shall be set up on the Company's website, which may be accessed with due guarantees by both individual shareholders and voluntary associations of shareholders that, pursuant to the provisions of said article, may be formed.

Proposals intended to be presented as a supplement to the Agenda announced in the notice of meeting, requests for adherence to such proposals, initiatives to reach the percentage required to exercise a minority right provided for in the Law, as well as offers or requests for voluntary representation may be published in the Forum.

Access to the Forum and the terms and conditions of its use and operation shall be governed by the provisions of this announcement and the rules of operation of the Electronic Shareholders' Forum, the contents of which may be viewed on the Company's website.

## **NOTARY'S INVOLVEMENT IN THE MEETING**

In accordance with the provisions of Article 203 of the Corporate Enterprises Act, the Board of Directors has agreed to request the assistance of a Notary Public for the purpose of drawing up the Minutes of the Meeting.

## **OTHER INFORMATION OF INTEREST TO SHAREHOLDERS**

It is noted for the record that the Ordinary General Shareholders' Meeting is expected to be held on first call, that is to say, on 14 June 2023 at the place and time indicated above.

All information and documentation of the General Shareholders' Meeting is also available to shareholders on the Company's website ([www.rovi.es](http://www.rovi.es)).

## **DATA PROTECTION**

The personal data provided by the shareholders to the Company for the exercise or delegation of their attendance and voting rights at the General Shareholders' Meeting, including the identification and verification of the prior formal legitimation thereof, those provided for such purposes by the banks and securities companies and agencies in which such shareholders have their shares deposited or held in custody or by the entity legally authorized to keep the book-entry registry, IBERCLEAR, and those obtained through the recording of the General Shareholders' Meeting (i.e., image and voice) shall be processed by the Company as the data controller for the purpose of managing the performance, fulfilment and control of the existing shareholder relationship (in particular, but not limited to, in relation to the organization, convening and holding of the General Meeting, the development, management and control of the exercise of their rights and of the Forum and the sending of information), for the holding, recording and dissemination of the General Meeting and for compliance with legal obligations. The processing of the data is necessary for such purposes and its legal basis is the execution of the shareholder relationship and the fulfilment of legal obligations.

*THIS TRANSLATION IS FOR INFORMATION PURPOSES ONLY.  
IN THE EVENT OF ANY DISCREPANCY BETWEEN THE SPANISH VERSION AND THE ENGLISH  
VERSION, THE SPANISH VERSION SHALL PREVAIL.*



The data may be communicated to the Notary who will attend the General Meeting, as well as to third parties who have recognised the right to information provided by law, or accessible to the public insofar as they are included in the documentation available on the Company's website ([www.rovi.es](http://www.rovi.es)) or stated at the General Meeting, whose holding may be subject to audiovisual recording (total or partial) and public dissemination on the Company's website ([www.rovi.es](http://www.rovi.es)) as well as on social networks and accredited media. The attendee is hereby informed that the General Meeting will be subject to audiovisual recording (image and voice) in order to allow the transparency and dissemination promoted by the applicable regulations. The legal basis for the processing of personal data consisting of image and voice is both the existence of a legitimate interest of the Company to record and broadcast the General Meeting, and the compliance of a legal obligation recognised in the rules and principles of transparency that apply to it. The shareholder is informed that there are mechanisms for exercising his rights as a shareholder other than attending the General Shareholders' Meeting.

In the area of image rights, we note that by attending the General Shareholders' Meeting (in person or remotely), the shareholder or his representative, gives consent to the taking of photographs, audiovisual recording of image and/or voice, as well as its reproduction and/or publication and dissemination in the terms indicated above.

Personal data will be retained for the duration of the shareholder relationship and thereafter for a period of six years for the sole purpose of any legal or contractual remedies, unless, by way of exception, a longer statute of limitations period applies to any possible legal or contractual remedies.

The data subject will have, in any case and when legally appropriate, the right of access, rectification, suppression, opposition, portability, limitation of processing, and any other rights that may be applicable in accordance with the applicable regulations by writing to Laboratorios Farmacéuticos Rovi, S.A., c/ Julián Camarillo, number 35, 28037, Madrid or to the e-mail address [protecciondedatos@rovi.es](mailto:protecciondedatos@rovi.es), along with a copy of his/her ID card or other official document that proves his/her identity. The data subject may also file a complaint with the Spanish Data Protection Agency ([www.aepd.es](http://www.aepd.es)).

In the event that the attendance card includes personal data referring to individuals other than the holder and in the event that a third party attends the General Meeting as a proxy of the shareholder, the shareholder must inform them of the points contained in the preceding paragraphs and comply with any other requirements that may be applicable for the correct transfer of personal data to the Company, without the Company having to take any additional action in terms of providing information or explanations to concerned parties. The personal data of such third parties will be processed in accordance with the provisions of this document, being subject to the same conditions and covered by the same legitimate bases as the shareholders' data.

If you have any doubts or questions to communicate to the Company in relation to the processing of your personal data, you may contact the Company's Data Protection Officer at the following e-mail address: [dp@rovi.es](mailto:dp@rovi.es).



# LABORATORIOS FARMACÉUTICOS ROVI, S.A.



C/ Julián Camarillo, 35 – 28037 Madrid  
Tel. 91 375 62 30 - Fax 91 304 78 81  
www.rovi.es

For further information, shareholders may contact the Company by sending an e-mail to [departamentolegal@rovi.es](mailto:departamentolegal@rovi.es).

Madrid, 9 May 2023

**The Chairman of the Board of Directors and Chief Executive Officer**  
**Mr Juan López-Belmonte Encina**

*THIS TRANSLATION IS FOR INFORMATION PURPOSES ONLY.  
IN THE EVENT OF ANY DISCREPANCY BETWEEN THE SPANISH VERSION AND THE ENGLISH  
VERSION, THE SPANISH VERSION SHALL PREVAIL.*



## LABORATORIOS FARMACÉUTICOS ROVI, S.A.

C/ Julián Camarillo, 35 – 28037 Madrid

Tel. 91 375 62 30 - Fax 91 304 78 81

[www.rovi.es](http://www.rovi.es)

### **PROPOSED RESOLUTIONS DRAFTED BY THE BOARD OF DIRECTORS AND PROPOSED TO THE ORDINARY GENERAL SHAREHOLDERS' MEETING OF LABORATORIOS FARMACÉUTICOS ROVI, S.A., CALLED FOR 14 JUNE 2023 AT THE FIRST QUORUM CALL AND 15 JUNE 2023 AT THE SECOND QUORUM CALL**

The following resolutions are proposed by the Board of Directors of Laboratorios Farmacéuticos Rovi, S.A. (“ROVI” or the “Company”) for approval of the General Shareholders' Meeting:

#### **ITEM ONE ON THE AGENDA**

**Examination and, if appropriate, approval of the individual financial statements of the Company (balance sheet, income statement, statement of changes in equity, statement of cash flows and notes to the financial statements) and of the consolidated financial statements of the Company with its subsidiaries (consolidated balance sheet, consolidated income statement, consolidated statement of comprehensive income, consolidated statement of changes in equity, consolidated statement of cash flows and consolidated notes to the financial statements) and of the consolidated management report of the Company with its subsidiaries, all for the year ended 31 December 2022.**

#### **PROPOSED RESOLUTION RELATING TO ITEM ONE**

The proposal is to approve the individual annual accounts of Laboratorios Farmacéuticos Rovi, S.A. (balance sheet, income statement, statement of changes in equity, cash flow statement and notes) and the consolidated accounts of Laboratorios Farmacéuticos Rovi, S.A. together with its subsidiaries (consolidated balance sheet, consolidated income statement, consolidated comprehensive income statement, consolidated statement of changes in equity and notes to the consolidated financial statements), as well as the Company's individual management report the Company's consolidated management report with its subsidiaries, all corresponding to the year ended 31 December 2022. They were drafted by the Board of Directors at its meeting held on 20 February 2023.

THIS TRANSLATION IS FOR INFORMATION PURPOSES ONLY.  
IN THE EVENT OF ANY DISCREPANCY BETWEEN THE SPANISH VERSION AND THE ENGLISH  
VERSION, THE SPANISH VERSION SHALL PREVAIL.



## **LABORATORIOS FARMACÉUTICOS ROVI, S.A.**

C/ Julián Camarillo, 35 – 28037 Madrid

Tel. 91 375 62 30 - Fax 91 304 78 81

[www.rovi.es](http://www.rovi.es)

### **ITEM TWO ON THE AGENDA**

**Examination and, if appropriate, approval of the statement of non-financial information included in the consolidated management report of the Company with its subsidiaries for the year ended 31 December 2022.**

### **PROPOSED RESOLUTION RELATING TO ITEM TWO**

The proposal is to approve the non-financial statement integrated into the consolidated management report of the Company and of its subsidiaries, corresponding to the year ended on 31 December 2022, as drafted by the Board of Directors.

*THIS TRANSLATION IS FOR INFORMATION PURPOSES ONLY.  
IN THE EVENT OF ANY DISCREPANCY BETWEEN THE SPANISH VERSION AND THE ENGLISH  
VERSION, THE SPANISH VERSION SHALL PREVAIL.*



**ITEM THREE ON THE AGENDA**

**Examination and, if appropriate, approval of the proposal for the application of the individual profit for the year ended 31 December 2022 and the proposal for the final dividend.**

**PROPOSED RESOLUTION RELATING TO ITEM THREE**

It is proposed to approve the application of the profit of Laboratorios Farmacéuticos Rovi, S.A. formulated by the Board of Directors in its meeting held on 20 February 2023 and the final dividend proposal detailed below:

- **Application of the individual profit for the year ended 31 December 2022**

The Board of Directors proposes to the General Shareholders' Meeting the application of all of the Company's profit for the year 2022, amounting to 39,116,103.39 euros, to dividends to be distributed among the shares entitled to receive it.

- **Final dividend**

In addition, it is proposed that an amount of 30,770,000.54 euros be allocated to dividends among the shares entitled to receive them with a charge to the unrestricted reserves recorded under the accounting item "Profit/(loss) from previous years".

Consequently, it is proposed to distribute a maximum amount, corresponding to a **fixed dividend of 1.2938 euros gross** per share entitled to receive it on the date on which the corresponding payment is made for all 54,016,157 ordinary shares outstanding at the date on which the annual accounts were drafted, which amounts to 69,886,103.93 euros.

The amount allocated to dividend is subject to change depending on the number of shares held by the Company as treasury shares on the date on which the rights to receive the dividend are generated.

The above amount will be paid on 5 July 2023, through Banco Santander, S.A., in accordance with the operating rules of Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A.U. (IBERCLEAR).

**ITEM FOUR ON THE AGENDA**

THIS TRANSLATION IS FOR INFORMATION PURPOSES ONLY.  
IN THE EVENT OF ANY DISCREPANCY BETWEEN THE SPANISH VERSION AND THE ENGLISH  
VERSION, THE SPANISH VERSION SHALL PREVAIL.



## **LABORATORIOS FARMACÉUTICOS ROVI, S.A.**

C/ Julián Camarillo, 35 – 28037 Madrid

Tel. 91 375 62 30 - Fax 91 304 78 81

[www.rovi.es](http://www.rovi.es)

### **Examination and, if appropriate, approval of the management work and performance of the Board of Directors during the year ended 31 December 2022.**

#### **PROPOSED RESOLUTION RELATING TO ITEM FOUR**

The proposal is to approve the management and activity of the Company's Board of Directors of the Company in the year ended 31 December 2022.

*THIS TRANSLATION IS FOR INFORMATION PURPOSES ONLY.  
IN THE EVENT OF ANY DISCREPANCY BETWEEN THE SPANISH VERSION AND THE ENGLISH  
VERSION, THE SPANISH VERSION SHALL PREVAIL.*



**ITEM FIVE ON THE AGENDA**

**Composition of the Board of Directors: Ratification and/or re-election, if appropriate, of directors for the term determined in the bylaws.**

**PROPOSED RESOLUTION RELATING TO ITEM 5.1**

***5.1 Re-election, if appropriate, of Mr Marcos Peña Pinto as an external independent director for the term determined in the bylaws.***

It is proposed to re-elect, at the proposal of the Appointments and Remuneration Committee, Mr Marcos Peña Pinto as a director of the Company with the category of external independent director for the term determined in the bylaws of four years as from the date of this General Shareholders' Meeting.

**PROPOSED RESOLUTION RELATING TO ITEM 5.2**

***5.2 Ratification and re-election, if appropriate, of Ms Teresa Corzo Santamaría as external independent director for the term determined in the bylaws.***

It is proposed to ratify the appointment by co-option and to re-elect, at the proposal of the Appointments and Remuneration Committee, Ms Teresa Corzo Santamaría as a director of the Company with the category of external independent director for the term determined in the bylaws of four years as from the date of this General Shareholders' Meeting.



## LABORATORIOS FARMACÉUTICOS ROVI, S.A.

C/ Julián Camarillo, 35 – 28037 Madrid

Tel. 91 375 62 30 - Fax 91 304 78 81

[www.rovi.es](http://www.rovi.es)

### ITEM SIX ON THE AGENDA

**Examination and approval, if appropriate, of the maximum annual remuneration of the members of the Board of Directors in their capacity as such for 2023.**

#### **PROPOSED RESOLUTION RELATING TO ITEM SIX**

It is proposed that the General Shareholders' Meeting of ROVI approve a total maximum annual remuneration of 1 million euros for members of the Board of Directors, in their capacity as such, for the 2023 financial year.

The Board of Directors may distribute this amount among its members, taking into account the functions and duties assigned to each director, their membership of the Board's Committees and other objective circumstances that it considers relevant.

THIS TRANSLATION IS FOR INFORMATION PURPOSES ONLY.  
IN THE EVENT OF ANY DISCREPANCY BETWEEN THE SPANISH VERSION AND THE ENGLISH  
VERSION, THE SPANISH VERSION SHALL PREVAIL.



**ITEM SEVEN ON THE AGENDA**

**Examination and approval, if appropriate, of the re-election of the auditors of the Company and its consolidated group for 2023.**

**PROPOSED RESOLUTION RELATING TO ITEM SEVEN**

To comply with the legal obligation to have the Company's annual accounts verified by an auditor, and acting on a proposal of the Audit Committee, the proposal is to re-appoint KPMG Auditores, S.L. as auditor of the accounts of the Company and its consolidated group corresponding to the year 2023.

It is noted that the auditing firm KPMG Auditores, S.L., has its registered office in Madrid, Paseo de la Castellana, 259C, Tax Identification Number B-78510153 and that it is registered in the Commercial Registry of Madrid, Volume 11,961, Folio 90, Section 8, Page M-188,007, entry 9; and in the Official Registry of Auditors under number S0702.

KPMG Auditores, S.L. may accept the appointment by any means valid in law.

It is also proposed to authorise the Company's Board of Directors, with the power of substitution, to enter into the corresponding service provision contract, including the clauses and conditions it considers appropriate, and also granting it the power to make any relevant changes in it in accordance with current law at any time.





## LABORATORIOS FARMACÉUTICOS ROVI, S.A.

C/ Julián Camarillo, 35 – 28037 Madrid

Tel. 91 375 62 30 - Fax 91 304 78 81

[www.rovi.es](http://www.rovi.es)

### ITEM EIGHT ON THE AGENDA

**Delegation of powers to formalise and register the resolutions adopted by the General Shareholders' Meeting and to carry out the mandatory filing of the financial statements.**

#### **PROPOSED RESOLUTION RELATING TO ITEM EIGHT**

Without prejudice to any delegations included in the above resolutions, the proposal is to authorise the delegation to the Board of Directors in the broadest possible terms, with the powers to subdelegate to any of its members and the non-member Secretary, all of them jointly and severally, any powers that are needed to interpret, enforce and make effective the resolutions adopted at this General Meeting, including the execution of any public or private documents that may be necessary, publication of any notices that may be required by law, registration in any registers that may be appropriate and the performance of any acts and procedures that may be necessary for that purpose; as well as other powers such as to rectify, clarify, interpret, complete, detail or specify, if appropriate, the resolutions adopted, in particular to rectify any substantive or formal defects, omissions or errors that may be found, including ones identified in the verbal or written qualification by the Commercial Registry, and which could hamper the effectiveness and registration of these resolutions and of their consequences in the Commercial Registry or any other registers; and, in particular, to carry out the necessary filing of financial statements in the Commercial Registry.

THIS TRANSLATION IS FOR INFORMATION PURPOSES ONLY.  
IN THE EVENT OF ANY DISCREPANCY BETWEEN THE SPANISH VERSION AND THE ENGLISH  
VERSION, THE SPANISH VERSION SHALL PREVAIL.



## LABORATORIOS FARMACÉUTICOS ROVI, S.A.

C/ Julián Camarillo, 35 – 28037 Madrid

Tel. 91 375 62 30 - Fax 91 304 78 81

[www.rovi.es](http://www.rovi.es)

### ADVISORY ITEM

#### ITEM NINE ON THE AGENDA

#### *Annual Report on the remuneration of the Company's directors*

#### PROPOSED RESOLUTION RELATING TO ITEM NINE

In compliance with article 541 of the Corporate Enterprises Act, the Board of Directors has prepared an annual report on Directors' remuneration corresponding to 2022, which was made available to shareholders not later than when this General Meeting was called, and which it is presenting to the General Shareholders' Meeting, acting on a previous report of the Appointments and Remuneration Committee. It is now submitting it to an advisory vote as a separate item on the Agenda.

The proposal is to approve the annual report on the Directors' remuneration corresponding to 2022 with an advisory vote.

\* \* \*

THIS TRANSLATION IS FOR INFORMATION PURPOSES ONLY.  
IN THE EVENT OF ANY DISCREPANCY BETWEEN THE SPANISH VERSION AND THE ENGLISH  
VERSION, THE SPANISH VERSION SHALL PREVAIL.